Bayer Healthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAYER HEALTHCARE, and what generic alternatives to BAYER HEALTHCARE drugs are available?
BAYER HEALTHCARE has twenty-nine approved drugs.
There are twenty-eight US patents protecting BAYER HEALTHCARE drugs. There is one tentative approval on BAYER HEALTHCARE drugs.
There are four hundred and twenty-six patent family members on BAYER HEALTHCARE drugs in fifty-nine countries and forty-nine supplementary protection certificates in seventeen countries.
Summary for Bayer Healthcare
| International Patents: | 426 |
| US Patents: | 28 |
| Tradenames: | 24 |
| Ingredients: | 14 |
| NDAs: | 29 |
| Patent Litigation for Bayer Healthcare: | See patent lawsuits for Bayer Healthcare |
Drugs and US Patents for Bayer Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | NUBEQA | darolutamide | TABLET;ORAL | 212099-001 | Jul 30, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 10,045,991 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Healthcare Llc | CLARITIN HIVES RELIEF | loratadine | SYRUP;ORAL | 020641-003 | Nov 19, 2003 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 9,447,104 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bayer Healthcare Llc | CLARITIN HIVES RELIEF REDITAB | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-003 | Nov 19, 2003 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Healthcare Llc | CHLOR-TRIMETON | chlorpheniramine maleate | TABLET, EXTENDED RELEASE;ORAL | 007638-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bayer Healthcare
International Patents for Bayer Healthcare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5107940 | ⤷ Try a Trial |
| South Korea | 20140129384 | ⤷ Try a Trial |
| Japan | 6914834 | ⤷ Try a Trial |
| Japan | 5763834 | ⤷ Try a Trial |
| Canada | 2967951 | ⤷ Try a Trial |
| Finland | 3699181 | ⤷ Try a Trial |
| Spain | 2312843 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bayer Healthcare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1986495 | 33/2019 | Austria | ⤷ Try a Trial | PRODUCT NAME: SEDAXAN ODER EIN TAUTOMER DAVON, FLUDIOXONIL UND METALAXYL M; NAT. REGISTRATION NO/DATE: 3979-0 20181130; FIRST REGISTRATION: NL 29317 20171229 |
| 3106463 | LUC00150 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SULFATE DE LAROTRECTINIB, Y COMPRIS L'HYDROGENOSULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923 |
| 3106463 | 301033 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LAROTRECTINIBSULFAAT, MET INBEGRIP VAN LAROTRECTINIBSULFAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/19/1385 20190923 |
| 3106463 | CR 2020 00013 | Denmark | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB OG/ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LAROTRECTINIBSULFAT, INKLUSIV LAROTRECTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20190923 |
| 3106463 | C20200005 00308 | Estonia | ⤷ Try a Trial | PRODUCT NAME: LAROTREKTINIIB;REG NO/DATE: EU/1/19/1385; 23.09.2019 |
| 2493858 | PA2020514 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: DAROLUTAMIDAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA ESTERIS; REGISTRATION NO/DATE: EU/1/20/1432 20200327 |
| 3106463 | C202030011 | Spain | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB Y/O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, PARTICULARMENTE SULFATO DE LAROTRECTINIB QUE INCLUYE HIDROGENOSULFATO DE LAROTRECTINIB; NATIONAL AUTHORISATION NUMBER: EU/1/19/1385; DATE OF AUTHORISATION: 20190919; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1385; DATE OF FIRST AUTHORISATION IN EEA: 20190919 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
